Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants

Publisher： Karger

E-ISSN： 1421-9662|137|4|207-208

ISSN： 0001-5792

Source： Acta Haematologica, Vol.137, Iss.4, 2017-05, pp. : 207-208

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 35-39

Karger

Access to resources Recommend Favorite

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 3, 2015-11 ,pp. : 344-354

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma – response to Moreau et al

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 604-605

John Wiley & Sons Inc

Access to resources Recommend Favorite

Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation

By  

Acta Haematologica, Vol. 132, Iss. 2, 2014-04 ,pp. : 226-232

Karger

Access to resources Recommend Favorite